Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Noven completes phase III program for low-dose paroxetine mesilate

March 22, 2012

Fate Therapeutics discloses new hedgehog pathway activators

March 22, 2012

EMA accepts lomitapide MAA for review

March 21, 2012

Karo Bio scientists discover new ER-beta ligands

March 21, 2012

Taisho reports novel sodium/glucose cotransporter 1 inhibitors

March 21, 2012

PROLOR Biotech launches pediatric trial of long-acting human growth hormone

March 21, 2012

Alnylam launches phase I trial of transthyretin-mediated amyloidosis therapy

March 20, 2012

Phase I trial assesses interaction between diabetes therapies

March 20, 2012

Novel hedgehog pathway activators divulged by Fate Therapeutics

March 19, 2012

Novel somatostatin sst5 receptor antagonists developed

March 19, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...